TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27519921
Drug: NIV combined
Normalized name: ReddyPort NIV Maintenance Kit KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: NIV combined with HFNC (pressure support=10, PEEP=5, FiO2=100% + flow=60 L/min, FiO2=100%)
Study: 22502790
Drug: TAM 20
Normalized name: sulbactam 20 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAM 20 mg daily orally (arm A)
Study: 22502790
Drug: TAM 10
Normalized name: sulbactam 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAM 10 mg daily starting simultaneously with bicalutamide (arm B)
Study: 17869051
Drug: Two-session brief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-session brief intervention (motivational enhancement therapy)
Study: 17869051
Drug: 3-month delayed-treatment
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3-month delayed-treatment control condition
Study: 10097506
Drug: Atarax (hydroxyzine)
Normalized name: hydroxyzine hydrochloride Oral Solution [Atarax]
DrugBank: Hydroxyzine (DB00557)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atarax (hydroxyzine) 50 mg daily for 28 days
Study: 1875413
Drug: Total doses
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total doses D1, D2, D3, and D4 differing by increments of 4.8 Gy, with all patients receiving two fractions of 1.2 Gy each daily 5 days a week.
Study: 1875413
Drug: Regimen D3
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen D3 (highest dose)
Study: 29122186
Drug: IMU-based inclinometer
Approvals — FDA: no, EMA: no, PMDA: no
Description: IMU-based inclinometer solutions
Study: 26888208
Drug: Bright white-light
Normalized name: Light White Mineral Oil
DrugBank: Light mineral oil (DB11579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bright white-light treatment (BLT, broad-wavelength light without UV 10,000 lux, irradiance 31.7 Watt/m(2))
Study: 24419823
Drug: Platelet-rich plasma
Normalized name: PLATELET-RICH PLASMA, AUTOLOGOUS
DrugBank: Platelet Rich Plasma (DB19295)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platelet-rich plasma (PRP) injection (3 cc)
Study: 24419823
Drug: Corticosteroid injection
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid injection (40 mg DepoMedrol)
Study: 20958144
Drug: Sidestream(®) nebulizer
Normalized name: Hydra-Neb
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sidestream(®) nebulizer coupled to a 110‐mL corrugated piece of tubing
Study: 17211605
Drug: Routine intravenous
Normalized name: Peace Out Acne Hero Routine KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine intravenous prophylaxis of isoxazolyl-penicillin
Study: 8018462
Drug: (S)-flurbiprofen 50
Normalized name: flurbiprofen 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: (S)-flurbiprofen 50 mg
Study: 8018462
Drug: (R)-flurbiprofen 50
Normalized name: flurbiprofen 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: (R)-flurbiprofen 50 mg
Study: 8018462
Drug: (R)-flurbiprofen 100
Normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: (R)-flurbiprofen 100 mg
Study: 3050904
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg inhaled gallopamil
Study: 3050904
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg inhaled gallopamil
Study: 25520249
Drug: Sibutramine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sibutramine treatment with diet and exercise
Study: 24460649
Drug: V-G haplotype
Normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: V-G haplotype (rs1800206, rs4253778)
Study: 15468574
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of albendazole (400 mg)
Study: 15468574
Drug: Nitazoxanide (1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitazoxanide (1.2 g single dose)
Study: 15468574
Drug: Nitazoxanide (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitazoxanide (15 mg/kg/day for three days)
Study: 15468574
Drug: Nitazoxanide (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitazoxanide (single dose)
Study: 2100983
Drug: Parenteral cefoxitin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral cefoxitin (given in three divided doses)
Study: 2100983
Drug: No parenteral
Approvals — FDA: no, EMA: no, PMDA: no
Description: No parenteral antibiotics (control group)
Study: 150816
Drug: Dry patch
Normalized name: LIDOCAINE 40 mg TOPICAL PATCH [Pain Relief 4% Lidocaine Dry Patch]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dry patch test (control)
Study: 31421668
Drug: Physiotherapy combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physiotherapy combined with corticosteroid injection
Study: 25835233
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 tablets (2000 IU/day) for six months
Study: 22307529
Drug: 0.1% gentamicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% gentamicin cream
Study: 19542998
Drug: Esmolol (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esmolol (0.5 mg/kg) during sevoflurane anesthesia
Study: 19542998
Drug: Esmolol (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esmolol (0.5 mg/kg) during desflurane anesthesia
Study: 9801975
Drug: High-dose aprotinin
Normalized name: Aprotinin
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-dose aprotinin during orthotopic liver transplantation (OLT)
Study: 9801975
Drug: High-dose aprotinin
Normalized name: Aprotinin
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-dose aprotinin during cardiac surgery
Study: 2154316
Drug: Chemotherapy for
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy for nonseminomatous germ cell tumors
Study: 2154316
Drug: Therapeutic approaches
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic approaches (surgery, chemotherapy, surgery plus chemotherapy)
Study: 842382
Drug: Levodopa treatment
Normalized name: Levodopa
DrugBank: Levodopa (DB01235)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Levodopa treatment for 6 months
Study: 30786861
Drug: 12-week moderate-intensity
Normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 12-week moderate-intensity exercise program (Borg perceived rating scale 13-14), at least three times weekly; one supervised group training and two home-based sessions
Study: 28005705
Drug: Distal treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Distal treatment applied mainly in the distal branches beyond the main bifurcation (n = 24)
Study: 28005705
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment restricted to the main renal artery (n = 21)
Study: 21665047
Drug: 15-mg modified-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15-mg modified-release tablet of metoclopramide every 12 hours
Study: 21665047
Drug: 10-mg immediate-release
Normalized name: IR-3535
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-mg immediate-release tablet of metoclopramide every 8 hours
Study: 14597948
Drug: aspirin plus
Normalized name: Aspirin Plus Antacid Extra Strength
Approvals — FDA: no, EMA: no, PMDA: no
Description: aspirin plus clopidogrel
Study: 10227336
Drug: Albuterol delivered
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol delivered via breath-actuated inhaler (Spiros)
Study: 10227336
Drug: Albuterol delivered
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol delivered via MDI (Ventolin)
Study: 1914371
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg phenylpropanolamine and 250 mg caffeine
Study: 1914371
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg phenylpropanolamine
Study: 15082437
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg caffeine
Study: 29797914
Drug: Catgut implantation
Normalized name: CATGUT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Catgut implantation at stellate ganglion combined with oral administration of alendronate sodium
Study: 29797914
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of alendronate sodium alone
Study: 28319454
Drug: Live attenuated
Normalized name: mumps, live attenuated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live attenuated hepatitis A vaccine
Study: 26151336
Drug: Ingesting 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ingesting 10 g fat
Study: 26151336
Drug: Ingesting 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ingesting 40 g fat
Study: 26151336
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (10 g fat)
Study: 26151336
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (40 g fat)
Study: 23964055
Drug: 400 g
Normalized name: Ambi 60 PSE-400 GFN
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 g high-glucoraphanin (HG) broccoli
Study: 23964055
Drug: 400 g
Normalized name: Ambi 60 PSE-400 GFN
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 g standard broccoli
Study: 23964055
Drug: 400 g
Normalized name: Ambi 60 PSE-400 GFN
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 g peas
Study: 16546473
Drug: Rosiglitazone (ROS)
DrugBank: Rosiglitazone (DB00412)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rosiglitazone (ROS) 4 mg daily for 12 weeks
Study: 9381523
Drug: Candoxatrilat (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candoxatrilat (100 mg i.v.)
Study: 8222497
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of contraceptive pill (250 micrograms levonorgestrel and 50 micrograms ethinyl estradiol)
Study: 8222497
Drug: Vaginal administration
Normalized name: Antiinflammatory products for vaginal administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal administration of contraceptive pill (250 micrograms levonorgestrel and 50 micrograms ethinyl estradiol)
Study: 29961187
Drug: Chromium picolinate
Normalized name: Chromium Picolinate
DrugBank: Chromium picolinate (DB11255)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chromium picolinate (Cr‐Pic) at 1.2 mg kg‐1
Study: 29961187
Drug: Chromium picolinate
Normalized name: Chromium Picolinate
DrugBank: Chromium picolinate (DB11255)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chromium picolinate (Cr‐Pic) at 1.8 mg kg‐1
Study: 29961187
Drug: Chromium picolinate
Normalized name: Chromium Picolinate
DrugBank: Chromium picolinate (DB11255)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chromium picolinate (Cr‐Pic) at 1.2 mg kg‐1 and 1.8 mg kg‐1
Study: 29961187
Drug: Low-protein diet
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-protein diet with 1.8 mg kg‐1 Cr
Study: 27346880
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) 0.5 mg/day for 6 months
Study: 19948383
Drug: Oxycodone 10mg
Normalized name: OXYCODONE 10MG/ACETAMINOPHEN 300MG TAB
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxycodone 10mg
Study: 22365897
Drug: Alprazolam 0.5mg
Normalized name: ALPRAZOLAM 0.5MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alprazolam 0.5mg + Oxycodone 10mg
Study: 15906783
Drug: Tamsulosin (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamsulosin (0.4 mg MR o.d.) for 12 weeks
Study: 10856736
Drug: Milrinone infusion
Normalized name: Milrinone
DrugBank: Milrinone (DB00235)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Milrinone infusion for 48 hours
Study: 10856736
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (placebo infusion for 48 hours)
Study: 6347152
Drug: Topical oxymetazoline
Normalized name: oxymetazoline Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical oxymetazoline hydrochloride 0.025%
Study: 23155956
Drug: Gabapentin 100
Normalized name: gabapentin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin 100 mg at night and 300 mg orally two hours before surgery
Study: 1734386
Drug: Erythromycin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin (10 days of oral treatment)
Study: 1734386
Drug: Mupirocin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mupirocin (10 days of topical treatment)
Study: 6093182
Drug: Desimipramine (DMI)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desimipramine (DMI) 50 mg IV
Study: 6093182
Drug: Desimipramine (DMI)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desimipramine (DMI) 25 mg IV
Study: 6093182
Drug: Chlorimipramine (CI)
Normalized name: Chlorimipramine
DrugBank: Clomipramine (DB01242)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chlorimipramine (CI) 25 mg IV
Study: 6093182
Drug: Sulpiride (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulpiride (100 mg IV)
Study: 6093182
Drug: Diazepam (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (10 mg IV)
Study: 29336628
Drug: Dietary supplement
Normalized name: dietary supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary supplement containing 178 mg satiereal, 100 mg naringin, and 2,000 IU vitamin D3 daily (SUPP)
Study: 20454497
Drug: Sildenafil (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil (50 mg dose)
Study: 17507738
Drug: 50 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 g/d of protein
Study: 17507738
Drug: 100 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 g/d of protein
Study: 17507738
Drug: 200 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 g/d of protein
Study: 17507738
Drug: All protein
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All protein intakes (50 g, 100 g, 200 g)
Study: 11803082
Drug: TA‐CD therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: TA‐CD therapeutic vaccine at 13 microg
Study: 11803082
Drug: TA‐CD therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: TA‐CD therapeutic vaccine at 82 microg
Study: 11803082
Drug: TA‐CD therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: TA‐CD therapeutic vaccine at 709 microg
Study: 11803082
Drug: TA‐CD therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: TA‐CD therapeutic vaccine (all doses combined)
Study: 12176783
Drug: Primary single-agent
Normalized name: Sodium primary phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primary single-agent epirubicin (120 mg/m(2) every 3 weeks for three cycles)
Study: 9825179
Drug: Coenzyme Q10
Normalized name: Coenzyme Q10
DrugBank: Ubidecarenone (DB09270)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Coenzyme Q10 (120 mg/d) for 28 days
Study: 2496977
Drug: Flecainide acetate
Normalized name: Flecainide Acetate
DrugBank: Flecainide (DB01195)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flecainide acetate 400 mg
Study: 337466
Drug: Osmic acid
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Osmic acid treatment
Study: 7304486
Drug: Bengal gram
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bengal gram dal (50 g carbohydrate)
Study: 7304486
Drug: Rajmah (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rajmah (50 g carbohydrate)
Study: 7304486
Drug: Wheat (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wheat (50 g carbohydrate)
Study: 7304486
Drug: Rice (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rice (50 g carbohydrate)
Study: 7304486
Drug: Dextrose (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextrose (50 g carbohydrate)
Study: 24401239
Drug: Simvastatin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin (20 mg/day) + POMx (1g/day)
Study: 24401239
Drug: Simvastatin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin (20 mg/day) + placebo
Study: 22677306
Drug: Diclofenac potassium
Normalized name: Diclofenac Potassium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac potassium 25 mg liquid capsule
Study: 22677306
Drug: Diclofenac potassium
Normalized name: Diclofenac Potassium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac potassium 2 x 12.5 mg tablets
Study: 18584249
Drug: Mosapride (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mosapride (15 mg by mouth with 50 ml of water three times a day starting on postoperative day 1)
Study: 18584249
Drug: Control (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (50 ml of water three times a day starting on postoperative day 1)
Study: 10496192
Drug: Vesnarinone 30
Normalized name: VESNARINONE
DrugBank: Vesnarinone (DB12082)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vesnarinone 30 mg
Study: 10496192
Drug: Vesnarinone 60
Normalized name: VESNARINONE
DrugBank: Vesnarinone (DB12082)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vesnarinone 60 mg
Study: 10496192
Drug: Vesnarinone (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vesnarinone (30 mg or 60 mg)
Study: 8929752
Drug: ketamine 6.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: ketamine 6.0 mg/kg j.i.
Study: 8929752
Drug: ketamine 3.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: ketamine 3.5 mg/kg j.i.
Study: 8929752
Drug: ketamine 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: ketamine 2.5 mg/kg j.i.
Study: 27492789
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg propranolol (PRO)
Study: 24875077
Drug: Dextromethorphan 60
Normalized name: DEXTROMETHORPHAN 60MG/GG 1200MG SA TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextromethorphan 60 mg 4 times a day
Study: 24875077
Drug: Clonidine 0.075
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine 0.075 mg 4 times a day
Study: 22538793
Drug: Initial case
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial case management (comprehensive, individual advice about available treatment possibilities for dementia patients)
Study: 16142248
Drug: 123I-ioflupane radiopharmaceutical
Normalized name: 123I-Ioflupane
DrugBank: Ioflupane I-123 (DB08824)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 123I-ioflupane radiopharmaceutical injected intravenously at a dose of 185 MBq
Study: 10360450
Drug: Capsaicin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsaicin (100 ml 1 mmol/l)
Study: 10360450
Drug: Physiological saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physiological saline (100 ml)
Study: 7353334
Drug: Aspirin 975
Normalized name: aspirin 975 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 975 mg every 6 hr, started 22 hr before phenytoin dose and continued for 48 hr
Study: 7353334
Drug: Aspirin 975
Normalized name: aspirin 975 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 975 mg every 6 hr
Study: 19048025
Drug: Fractional dose
Normalized name: plasma protein fraction Injection [Plasmanate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fractional dose 1/5 of the meningococcal polysaccharide vaccine
Study: 19048025
Drug: Fractional dose
Normalized name: plasma protein fraction Injection [Plasmanate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fractional dose 1/10 of the meningococcal polysaccharide vaccine
Study: 19048025
Drug: Full dose
Normalized name: BayRHo-D Full Dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full dose of the meningococcal polysaccharide vaccine
Study: 19048025
Drug: Fractional doses
Normalized name: plasma protein fraction Injection [Plasmanate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fractional doses (1/5 and 1/10) of the meningococcal polysaccharide vaccine
Study: 19048025
Drug: All doses
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All doses of the meningococcal polysaccharide vaccine
Study: 8575589
Drug: Aerosol administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aerosol administration of antipseudomonal antibiotics
Study: 8575589
Drug: Placebo (nebulized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (nebulized solution)
Study: 8575589
Drug: Aerosol administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aerosol administration of antipseudomonal antibiotics as adjunct to intravenous therapy
Study: 8575589
Drug: Aerosol maintenance
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aerosol maintenance treatment with appropriate antibiotic in high enough dosage
Study: 6109855
Drug: Thrice-weekly isoniazid,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrice-weekly isoniazid, rifampicin, streptomycin, and ethambutol (without pyrazinamide)
Study: 6109855
Drug: Thrice-weekly isoniazid,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrice-weekly isoniazid, rifampicin, streptomycin, and pyrazinamide
Study: 6109855
Drug: Thrice-weekly isoniazid,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrice-weekly isoniazid, rifampicin, pyrazinamide, and ethambutol
Study: 6109855
Drug: Thrice-weekly isoniazid,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrice-weekly isoniazid, rifampicin, pyrazinamide, and streptomycin
Study: 6109855
Drug: Daily isoniazid,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily isoniazid, rifampicin, pyrazinamide, and ethambutol
Study: 31397120
Drug: Intratracheal administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intratracheal administration of corticosteroids (IAC)
Study: 25746670
Drug: 24 or
Normalized name: Theo-24 Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24 or 60 weeks of combination antiretroviral therapy (cART)
Study: 23917585
Drug: Intravenous tissue
Normalized name: allogeneic processed thymus tissue Drug Implant [Rethymic]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous tissue plasminogen activator (100 mg) or streptokinase (1,500,000 U)
Study: 11215366
Drug: Human albumin
Normalized name: Human albumin
DrugBank: Albumin human (DB00062)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human albumin (5-8 g/l ascites)
Study: 18476179
Drug: Ampicillin/Sulbactam (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ampicillin/Sulbactam (2 g/1 g, IV every 6 h)
Study: 18476179
Drug: Cefoxitin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefoxitin (2 g, IV every 6 h)
Study: 7792559
Drug: Cefuroxime (thrice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefuroxime (thrice daily until the end of the second postoperative day)